HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET.
ZAVZPRET™ (zavegepant) nasal spray
Initial U.S. Approval: 2023
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Nasal spray: 10 mg (3)
Patients with a history of hypersensitivity reaction to zavegepant or to any of the components of ZAVZPRET. (4)
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity Reactions including facial swelling and urticaria have occurred with ZAVZPRET. (5.1)
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.